Enrico Martin

261 Morbidity and function loss after resection of MPNST Table 3 Differences between patients with and without function loss. Variable At least M3 Less than M3 P No loss of critical sensation Loss of critical sensation P N 393 157 228 76 Age (years) 0-18 32 (8.1%) 19 (12.1%) 0.10 29 (12.7%) 8 (10.5%) 0.04 19-60 271 (69.0%) 113 (72.0%) 147 (64.5%) 60 (78.9%) 60+ 90 (22.9%) 25 (15.9%) 52 (22.8%) 8 (10.5%) Male gender 201 (51.1%) 88 (56.4%) 0.31 124 (54.6%) 34 (44.7%) 0.19 NF1 102 (27.3%) 78 (52.0%) <0.001 78 (35.6%) 36 (50.0%) 0.04 Tumor site Extremities 141 (35.9%) 83 (52.9%) <0.001 87 (38.2%) 41 (53.9%) <0.001 Brachial plexus 19 (4.8%) 25 (15.9%) 11 (4.8%) 19 (25.0%) Head and neck 56 (14.2%) 7 (4.5%) 35 (15.4%) 0 (0.0%) Pelvic 17 (4.3%) 21 (13.4%) 14 (6.1%) 11 (14.5%) Core 156 (39.7%) 20 (12.7%) 77 (33.8%) 5 (6.6%) Major nerve of origin 95 (24.2%) 105 (66.9%) <0.001 59 (34.7%) 46 (86.8%) <0.001 Nerve type Motor 6 (6.5%) 2 (1.9%) 10 (10.4%) 0 (0.0%) Mixed 49 (52.7%) 96 (92.3%) <0.001 59 (61.5%) 65 (94.2%) 0.02 Sensory 38 (40.9%) 6 (5.8%) 27 (28.1%) 4 (5.8%) Tumor size <5cm 97 (35.3%) 24 (18.0%) 0.001 54 (29.0%) 14 (20.6%) 0.09 5-10cm 106 (38.5%) 60 (45.1%) 65 (34.9%) 34 (50.0%) ≥10cm 72 (26.2%) 49 (36.8%) 67 (36.0%) 20 (29.4%) Deep-seated tumor 157 (69.4%) 101 (96.2%) <0.001 141 (82.2%) 51 (96.2%) 0.02 Motor deficit at presentation 35 (9.5%) 49 (32.0%) <0.001 33 (15.1%) 27 (36.5%) <0.001 11